On the filings, Eli Lilly (LLY) is the stronger stock right now — higher on our blended fundamentals-plus-verdict read, and we currently rate it BUY.
Hyper-growth telehealth with 74% gross margins and real cash flow, but a its multiple and acute regulatory risk cap it.
GLP-1 juggernaut: +45% revenue, +96% EPS, 78% ROE fund a catalyst-rich pipeline; rich at 48x but the growth backs it.
| Metric | HIMS | LLY |
|---|---|---|
| Fundamentals score | 69 | 90 |
| Revenue growth (YoY) | +59.0% | +44.7% |
| Net income growth (YoY) | +1.8% | +94.9% |
| Net margin | 5.5% | 31.7% |
| Return on equity | 23.7% | 77.8% |
| ROIC (est.) | 15.4% | — |
| Liabilities / Equity | 2.98 | — |
| Piotroski F-score | 4 / 9 | 6 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:52 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 19, 2026, 1:54 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.